Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

ABSTRACT:

SUBMITTER: Badar T 

PROVIDER: S-EPMC10879201 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature